GW501516 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Risk of addiction and abuse Potentially fatal respiratory depression Lethal overdose in accidental ingestion QT prolongation Neonatal opioid withdrawal syndrome in children of pregnant women CYP450 drug interactions Risks when used with alcohol, benzodiazepines, and other CNS depressants. A certified opioid treatment program is required under federal law (42 CFR 8.12) when dispensing methadone for the treatment of opioid addiction.
This was Merck's first use of the designation and the reduction in regulatory risk was one of the reasons management was willing to put company resources into development. In 2013, the United States Adopted Name (USAN) name was changed from lambrolizumab to pembrolizumab. In that year clinical trial results in advanced melanoma were published in The New England Journal of Medicine. This was part of the large phase I NCT01295827 trial. In September 2014, the US Food and Drug Administration (FDA) approved pembrolizumab under the Fast Track Development Program. It is approved for use following treatment with ipilimumab, or after treatment with ipilimumab and a BRAF inhibitor in advanced melanoma patients who carry a BRAF mutation. As of 2015, the only PD-1/PD-L1 targeting drugs on the market are pembrolizumab and nivolumab. By April 2016, Merck applied for approval to market the drug in Japan and signed an agreement with Taiho Pharmaceutical to co-promote it there. In July 2015, pembrolizumab received marketing approval in the European Union. In October 2015, the US FDA approved pembrolizumab for the treatment of metastatic non-small cell lung cancer (NSCLC) in people whose tumors express PD-L1 and who have failed treatment with other chemotherapeutic agents. In July 2016, the US FDA accepted for priority review an application for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after a platinum-based chemotherapy.
== Mitochondrial fatty acid synthesis == Although fatty acid synthesis in eukaryotes is traditionally considered a cytosolic process (FAS/FASI), a distinct de novo mitochondrial pathway (mtFAS/mtFASII) also exists, that is orthologous to the bacterial FAS II system. First described in 1990 in Neurospora crassa, this conserved pathway has since been shown to be essential for mitochondrial biogenesis and cellular respiration. Accordingly, mitochondrial fatty acid synthesis is required for embryonic survival in mammals and for respiratory growth in yeast.
==== Congress of South African Students ==== Accounts of the uprising typically accord a central role to black young adults – known in the anti-apartheid movement as "young lions" or "comrades" – who became the "shock troops" of the revolt. Their largest and most prominent organisational base was COSAS, another UDF affiliate that was founded in 1979, with a local branch in Vaal from March 1980. COSAS apparently played an important role in politicising the youth of Vaal, including by encouraging them to support the VCA, and many of the most militant participants in the uprising were formally or informally affiliated to COSAS.
Sources: en.wikipedia.org
Contamination has also been seen in water wells and other sources of drinking water. This contamination is seen in US, United Kingdom, Germany, Japan, and Canada, but information from most developing countries is nearly nonexistent. The lack of information on PFAS contamination in developing countries, especially those in Africa, are due to structural socioeconomic inequality and lack of access to the expensive laboratory capabilities required for PFAS quantification.
Commander-in-Chief of the Ukrainian Armed Forces Oleksandr Syrskyi confirmed that Ukrainian forces had retreated from the villages of Berdychi, Semenivka, and Novomykhailivka in Donetsk Oblast. He also said that Ukrainian forces had regained control of Nestryha Island in the Dnipro River delta in Kherson Oblast. The ISW assessed that Ukrainian soldiers suffered a "one-to-three manpower disadvantage" northwest of Avdiivka. Russia claimed to have shot down 17 drones over Belgorod, Kursk, Kaluga and Bryansk Oblasts. Russian milbloggers claimed that Ukraine conducted an unsuccessful ATACMS strike on Russian air defense units at Cape Tarkhankut, Crimea. Ukraine announced that it would partially suspend its adherence to the European Convention on Human Rights to be able to fully apply martial law on its territory.
Cytometry by time of flight, or CyTOF, is an application of mass cytometry used to quantify labeled targets on the surface and interior of single cells. CyTOF allows the quantification of multiple cellular components simultaneously using an ICP-MS detector. CyTOF takes advantage of immunolabeling to quantify proteins, carbohydrates or lipids in a cell. Targets are selected to answer a specific research question and are labeled with lanthanide metal tagged antibodies. Labeled cells are nebulized and mixed with heated argon gas to dry the cell containing particles. The sample-gas mixture is focused and ignited with an argon plasma torch. This breaks the cells into their individual atoms and creates an ion cloud. Abundant low weight ions generated from environmental air and biological molecules are removed using a quadrupole mass analyzer. The remaining heavy ions from the antibody tags are quantified by Time-of-flight mass spectrometry. Ion abundances correlate with the amount of target per cell and can be used to infer cellular qualities. Mass spectrometry's sensitivity to detect different ions allows measurements of upwards of 50 targets per cell while avoiding issues with spectral overlap seen when using fluorescent probes. However, this sensitivity also means trace heavy metal contamination is a concern. Using large numbers of probes creates new problems in analyzing the high dimensional data generated.
Second Cold War Observatory official website "Welcome to Cold War Two: historian Niall Ferguson on geopolitics in 2026" on YouTube Media related to Cold War II at Wikimedia Commons Quotations related to Second Cold War at Wikiquote The dictionary definition of Cold War II at Wiktionary Learning materials related to Cold War II at Wikiversity
Special considerations Some nutrients that require special consideration include protein, calcium, vitamin D, vitamin B12, taurine, L-carnitine, and omega-3 fatty acids, particularly DHA and EPA. Although their sources are more limited without animal products, it is possible to formulate a diet adequate in these nutrients through plant and synthetic sources. A review recommends a cautious approach to vegan dog food given "the lack of large population-based studies" as of 2023 and that commercial foods are used if guardians wish to implement a vegan diet. Potential risks in feeding a plant-based diet include alkaline urine and nutrient inadequacy, especially in homemade diets. Adherence to recommendations by reliable sources is strongly advised. β-mannanase supplementation may aid crude protein digestion in dogs fed a diet high in plant protein.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.